-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluticasone Propionate in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluticasone Propionate in Osteoarthritis Pain report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluticasone Propionate in Osteoarthritis Pain Drug Details: Fluticasone propionate (EP-104)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Carbidopa + Levodopa) in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Carbidopa + Levodopa) in Parkinson's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Carbidopa + Levodopa) in Parkinson's Disease Drug Details: IPX-203...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Myasthenia Gravis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLYB-116 in Myasthenia Gravis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLYB-116 in Myasthenia Gravis Drug Details: RLYB-116 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ceftibuten + Ledaborbactam Etzadroxil) in Urinary Tract Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ceftibuten + Ledaborbactam Etzadroxil) in Urinary Tract Infections report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Ceftibuten + Ledaborbactam Etzadroxil) in Urinary Tract...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ceftibuten + Ledaborbactam Etzadroxil) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ceftibuten + Ledaborbactam Etzadroxil) in Pyelonephritis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Ceftibuten + Ledaborbactam Etzadroxil) in Pyelonephritis Drug Details: Fixed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fluticasone Propionate in Eosinophilic Esophagitis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fluticasone Propionate in Eosinophilic Esophagitis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fluticasone Propionate in Eosinophilic Esophagitis Drug Details: Fluticasone propionate (EP-104)...
-
Analyst Opinions
NewGastronomy Travel – Key Trends and Market Analysis by Destinations, Challenges and Opportunities, 2024 Update
Gastronomy Travel Market Report Overview Gastronomy tourism is a growing segment of the travel industry. It involves an individual’s exploration of local cuisine and gastronomy as a part of their overall travel experience. A country’s local cuisine reflects the culture’s eating habits and is one of the simplest ways to learn more about its history, culture, and people. Gastro-tourism extends beyond the food that is eaten. It delves into how, where when, and the reason behind eating a specific food....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLYB-116 in Paroxysmal Nocturnal Hemoglobinuria Drug Details: RLYB-116 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tarlatamab in Small-Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Tarlatamab in Small-Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tarlatamab in Small-Cell Lung Cancer Drug Details: Tarlatamab-dlle (Imdelltra) acts...